Anti-IgE [EPC]

50358 reported adverse events

Drugs of this class: OMALIZUMAB

These side effects are most commonly reported by patients taking drugs of the Anti-IgE [EPC] class:

# Side effect Count
0 ASTHMA 8339
1 DYSPNOEA 6839
2 URTICARIA 5504
3 DRUG INEFFECTIVE 4696
4 COUGH 4661
5 FATIGUE 4084
6 MALAISE 3826
7 HEADACHE 3701
8 PRURITUS 3554
9 WHEEZING 3463
See all common reactions for Anti-IgE [EPC]

Drugs of the Anti-IgE [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 FORCED EXPIRATORY FLOW DECREASED 45 0.6081
1 FORCED EXPIRATORY VOLUME DECREASED 1234 0.5901
2 URTICARIA THERMAL 53 0.5824
3 CHRONIC SPONTANEOUS URTICARIA 281 0.5735
4 SMOKE SENSITIVITY 113 0.5407
5 TOTAL LUNG CAPACITY INCREASED 65 0.5285
6 PERFUME SENSITIVITY 173 0.4832
7 BLOOD IMMUNOGLOBULIN E DECREASED 42 0.4200
8 BRONCHOPULMONARY ASPERGILLOSIS ALLERGIC 198 0.4066
9 EXPOSURE TO ALLERGEN 47 0.3950
See all enriched reactions for Anti-IgE [EPC]